Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
SwanBio

19.01.2021

SwanBio Therapeutics Appoints Alison Lawton to Board of Directors

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointment of Alison Lawton to the company’s Board of Directors.
Achilles Therapeutics

08.01.2021

Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager

Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Arjan Roozen as VP, Site Head and General Manager, with responsibility for scaling up Achilles’ manufacturing operations to supply cell therapy products for late-stage clinical studies and commercial supply.
Purespring

08.01.2021

Purespring appoints new Chief Executive Officer

Purespring Therapeutics (Purespring), a kidney-focused AAV gene therapy company, announces that it is intended to appoint Richard Francis as Chief Executive Officer following the completion of its Series A financing of £45.0 million, from 1 February 2021.
Achilles Therapeutics

07.01.2021

Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference
Autolus

06.01.2021

Autolus Therapeutics provides business outlook for 2021 & 2022

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an updated business outlook, strengthening its focus on its potentially transformational CAR T cell therapy candidate, AUTO1, which is being investigated in relapsed / refractory adult B-Acute Lymphoblastic Leukemia (ALL).
SwanBio

06.01.2021

SwanBio Therapeutics Appoints Scott McMillan, Ph.D., as Chief Technical Officer

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that Scott McMillan, Ph.D., has been appointed Chief Technical Officer.
Freeline

04.01.2021

Freeline to participate at Conferences during January 2021

Freeline Therapeutics Holdings plc (Nasdaq: FRLN), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021.
Autolus

04.01.2021

Autolus Therapeutics to participate in Investor Conferences through January 2021

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.
Gyroscope

18.12.2020

Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases

Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope has an exclusive option to the intellectual property associated with, and arising from, the research conducted under the agreement.
Achilles Therapeutics

09.12.2020

Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours today announced the appointment of Lee M. Stern as VP, IR & External Communications where he will lead investor and financial communications activities.

Load More